Author: Zeteo Biomedical LLC
-
Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines
PFLUGERVILLE, Texas — Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo’s latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.
-
Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals
AUSTIN, Texas — Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its “Oral Delivery Device and Methods” (US Patent 10238577). This latest patent expands the capabilities of Zeteo’s ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual…
-
Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program
AUSTIN, Texas — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.